LBDA

Biomarkers in LBD, a clinical study by the DLB Consortium (DLBC)

What is this study about?

The purpose of this study is to collect clinical information, brain imaging scans, and biological samples from people that have dementia with Lewy bodies. This information will help researchers gain a better understanding of the biology behind LBD.

What is involved?

Participants will be enrolled in the study and have annual study visits for several years. This allows for researchers to collect vital information and samples over time as the disease evolves.

Participants will have an initial assessment that includes an MRI and a DaTScan. The study coordinator will provide further information as to what the study entails.

Who can participate?

Those that meet the following may be able to take part in the study:

  • Has a diagnosis of
    • probable dementia with Lewy bodies (DLB) or
    • mild cognitive impairment that is suspected to progress to DLB
  • Has a study partner who is able to attend study visits

Study Locations:

State City Academic Center Study Coordinator Email and Phone Number
OH Cleveland Cleveland Clinic Lou Ruvo Center for Brain Health Anna Long longa2@ccf.org
216-445-1155
PA Philadelphia Thomas Jefferson University Julie Maillie julie.maillie@jefferson.edu
215-955-8922
PA Philadelphia University of Pennsylvania Sophia Dominguez sodo@mail.med.upenn.edu
215-662-6144

Study Sponsor:

National Institutes of Health and The Lewy Body Dementia Association

Still have questions?

Please contact Anna Long, Study Coordinator, Cleveland Clinic at 216-445-1155 or LONGA2@ccf.org